

Submicroscopic chromosomal imbalances in idiopathic Silver–Russell syndrome (SRS): the SRS phenotype overlaps with the 12q14 microdeletion syndrome

S Spengler,¹ N Schönherr,¹ G Binder,² H A Wollmann,² S Fricke-Otto,³ R Mühlenberg,³ B Denecke,⁴ M Baudis,⁵ T Eggermann¹

¹Institute of Human Genetics, University Hospital, RWTH Aachen, Germany

²University-Children's Hospital, Pediatric Endocrinology and Diabetology, Tübingen, Germany

³Children's Hospital, Helios Hospital, Krefeld, Germany

⁴Interdisciplinary Centre for Clinical Research, IZKF "BIOMAT", RWTH Aachen, Germany

⁵Institute of Molecular Biology, University of Zürich, Zurich, Switzerland

Correspondence to

Thomas Eggermann, Institute of Human Genetics, University Hospital, RWTH Aachen, Pauwelsstr 30, D-52074 Aachen, Germany; teggermann@ukaachen.de

Received 4 June 2009

Revised 2 July 2009

Accepted 2 July 2009

ABSTRACT

Silver–Russell syndrome (SRS) is a heterogeneous disorder associated with intrauterine and postnatal growth restriction, body asymmetry, a relative macrocephaly, a characteristic triangular face and further dysmorphisms. In about 50% of patients, genetic/epigenetic alterations can be detected: >38% of patients show a hypomethylation of the IGF2/H19 imprinting region in 11p15, whereas the additional 10% carry a maternal uniparental disomy of chromosome 7. In single cases, cytogenetic aberrations can be detected. Nevertheless, there still remain 50% of SRS patients without known genetic/epigenetic alterations. To find out whether submicroscopic imbalances contribute to the aetiology of SRS, 20 idiopathic SRS patients were screened with the Affymetrix GeneChip Human Mapping 500 K array set.

Apart from known apathogenic copy number variations, we identified one patient with a 12q14 microdeletion. The 12q14 microdeletion syndrome is characterised by dwarfism but it additionally includes mental retardation and osteopoikilosis. The deletion in our patient is smaller than those in the 12q14 microdeletion carriers but it also affects the *LEMD3* and the *HMGA2* genes. *LEMD3* haploinsufficiency and point mutations have been previously associated with osteopoikilosis but radiographs of our patient at the age of 16 years did not reveal any hint for osteopoikilosis lesions. Haploinsufficiency of *HMGA2* is probably responsible for aberrant growth in 12q14 microdeletion syndrome. However, in this study, a general role of *HMGA2* mutations for SRS was excluded by sequencing of 20 idiopathic patients.

In conclusion, our results exclude a common cryptic chromosomal imbalance in idiopathic SRS patients but show that chromosomal aberrations are relevant in this disease. Thus, molecular karyotyping is indicated in SRS and should be included in the diagnostic algorithm.

Silver–Russell syndrome (SRS, Online Mendelian Inheritance in Man 180860) is a clinically and genetically heterogeneous disorder that is mainly characterised by severe intrauterine and postnatal growth retardation and a characteristic small, triangular face. The disease is associated with failure to thrive and additional dysmorphic features, including fifth finger clinodactyly and hemihypoplasia. Although a clinical scoring system to assist the diagnosis has recently been suggested,¹

the accuracy of diagnosis is influenced by the experience of the clinical investigator. Furthermore, the clinical picture of SRS in adulthood is less clear than in early childhood.

The clinical heterogeneity is reflected by the heterogeneous genetic/epigenetic findings in SRS patients: in about 10% of cases, a maternal uniparental disomy of chromosome 7 (UPD(7)mat) can be detected, whereas >38% carry a methylation defect in the telomeric imprinted region on chromosome 11p15 (for review²). Indeed, the 11p15 epimutation carriers often show the more typical SRS phenotype, while UPD(7)mat carriers are more mildly affected (for review³). Nevertheless, many exceptions have been reported, thereby making a strict genotype–phenotype correlation impossible. In addition to these two major disturbances, several SRS patients carry microscopically detectable structural aberrations affecting numerous chromosomes, but only chromosomes 7, 11 and 17 were repeatedly involved in individuals fulfilling strict diagnostic criteria of SRS (figure 1).

Up to now, chromosomal analysis in SRS has been based on conventional karyotype analysis, but a systematic screen for (sub)microscopic disturbances has not yet been performed. With the development of array-based genomic screening techniques, a new powerful tool for detection of cryptic imbalances has recently become available. While several new microdeletion syndromes have been identified using genomic array technology (for review⁴), the search for genomic imbalances has nearly always been focused on patients with mental retardation and facultative clinical features. The need to check SRS patients for submicroscopic chromosomal imbalances was recently illustrated by the identification of two SRS patients carrying 11p15 duplications with a size of 1 and 5.6 Mb, respectively (for review²).

We screened a cohort of idiopathic SRS patients for cryptic chromosomal imbalances by single nucleotide polymorphism (SNP) oligonucleotide arrays, thereby identifying one carrier of a 12q14 microdeletion. Within this region, the gene of the non-histone chromosomal protein *HMGA2* is localised. The identification of a *HMGA2* mutation in the “pygmy” mouse indicated that *HMGA2* plays a role in aberrant growth and development.⁵ We therefore sequenced the coding region of *HMGA2* in the deletion carrier as well as in 19 further SRS patients without 11p15 epimutation.




Figure 1 Chromosomal aberrations and uniparental disomies (UPDs) in SRS: review on types, frequencies and affected genomic regions. A complete list of references describing chromosomal aberrations in Silver–Russell syndrome is available on request. The 12q14 microdeletion in our patient is indicated by an arrow.

The study population consisted of 20 patients with SRS, ascertained as part of ongoing molecular investigations on SRS. The diagnosis of SRS was based on the following criteria: intrauterine growth retardation (birth weight or length below the third percentile), lack of postnatal catch-up growth, and at least two of the following criteria: typical face, relative macrocephaly and skeletal asymmetry. In all patients, 11p15 epimutation and UPD(7)mat had previously been excluded. The study was approved by the ethical committee of the University Hospital Aachen.

Genomic DNA of the probands was isolated from peripheral lymphocyte cells by a simple salting-out procedure.

All samples were investigated by microarray typing. The used 500 K array (Affymetrix, High Wycombe, UK) consists of two arrays, the *NspI* kit and the *StyI* kit, which together include >500 000 SNPs. DNA was processed according to the manufacturer's instructions. Hybridisation and washing were performed according to the manufacturer's manual. Arrays were recorded using an Affymetrix GeneChip Scanner 3000 7G. Data processing including quality assessment was performed using the R statistical framework (<http://www.r-project.org>) with dedicated extensions from the "aroma.affymetrix" project.⁶ Copy number segmentation results were visualised using tools developed for the Progenetix project (<http://www.progenetix.net>).⁷ The 12q14 microdeletion was then confirmed by quantitative PCR and by typing of the Affymetrix GeneChip Genome-Wide Human SNP 6.0 array.

Direct sequencing of the coding region of the *HMGA2* gene was performed by using the BigDye Terminator Cycle Sequencing System (Applied Biosystems, Weiterstadt, Germany). Primers and PCR conditions are available on request. Samples were electrophoresed on an automatic ABI3130 sequencing system (Applied Biosystems).

Apart from numerous known pathogenic copy number variations (CNVs) in each patient, we identified altogether seven different so far unregistered copy number alterations (CNAs) in 5 of the 20 patients (table 1). Six affected regions did not harbour genes and were therefore excluded from further analysis. However, the screening for submicroscopic imbalances in 20 idiopathic SRS patients did not provide evidence for a common chromosomal aberration in this syndrome. This finding is not surprising if we consider the extreme clinical but also genetic/epigenetic heterogeneity in this disease. Also, this observation is in line with reports from other genomic screening studies reporting the heterogeneity of pathological CNAs in patients analysed because of one or related phenotypical studies (eg, studies on mental retardation, epilepsy and autism; for review⁴).

Nevertheless, the identification of 1 among 20 so far idiopathic SRS patients carrying a microdeletion underlines the necessity to routinely test SRS patients by molecular karyotyping.

In this patient (SR29), we detected a de novo 1.35 Mb deletion in 12q14; among others, this deletion includes the *LEMD3* and the *HMGA2* genes (fig 2). The girl was the second

Table 1 Overview on the six patients identified by 500 K microarray typing as carriers of so far unreported (de novo) copy number variations (CNVs)/ copy number alterations (CNAs), and the affected regions

Patient	Chromosome	Gain/loss	Size	Genes affected	Interpretation
SR29	12q14	Loss	1.3 Mb	Yes (see fig 2)	CNA
SR115	8q21	Gain	710 kb	No	CNV
	16q21	Loss	12 kb	No	CNV
SR89	9p23	Loss	103 kb	No	CNV
SR95	18q22	Loss	51 kb	No	CNV
SR104	6q12	Loss	43.1 kb	No	CNV
SR63	14q12	Loss	4 kb	No	CNV

child of healthy unrelated parents. Her father's height is 185 cm, while her mother's height is 166 cm. Family history is unremarkable.

Intrauterine growth retardation was noted in the 20th week of pregnancy. The child was born at term, length at birth was 46 cm (-2.59 SD) and weight was 2700 g (-1.83 SD). Apgar scores were 10 and 10. Psychomotor development was unremarkable. Feeding difficulties and a squeaky voice were reported. At an age of 1 year and 9 months, the girl spoke 10 words.

The patient was referred for clinical evaluation at age 1 year and 9 months, her height was 70.8 cm (-4.5 SD), her weight was 6800 g (-5.4 SD) and occipitofrontal circumference was 43.7 cm (-3.3 SD) (table 2). In addition to relative macrocephaly, she presented a prominent forehead, a slightly triangular face, slightly dysplastic ears and clinodactyly of the fifth digit. She showed no evidence for lateral asymmetry or skeletal abnormalities.

At the age of 16 years, radiographic evaluation of the right tibia and fibula as well as the right foot did not reveal any

Figure 2 Local Affymetrix Genotyping 6.0 signal distribution pattern and segmentation result in patient SR29 (SR0029). A deletion in 12q14 can be observed, affecting the whole *HMG2* and *LEMD3* coding regions and overlapping with the previously reported 12q14 microdeletion syndrome as illustrated by the DECIPHER entries.




Table 2 Clinical features of Silver–Russell syndrome (SRS) patients, of 12q14 microdeletion carriers and our case

SRS features	General SRS population ¹³ (%)	General SRS population (n=50) ¹⁴ (%)	12q14 microdeletion carriers* (n=4) ^{8–10}	Our patient*
Birth weight below the third percentile	94	86	2/4	+
Short stature	99	86	4/4	+
Hemihypotrophy	51	34	0/4	–
Muscular hypotrophy/hypotony	45		1/4	–
Relative macrocephaly	64	70	1/4	+
Triangular face	79	62	1/4	(+)
Down-slanting corners of the mouth	46		1/4	–
Irregular teeth	28		–	–
Ear anomalies	53		–	–
Clinodactyly V	68	56	–	+
Brachydactyly V	48		–	–
Syndactyly of toes II/III	19		–	–
Simian crease	25		–	–
Café-au-lait spots	19	4	–	–
Psychomotor retardation	37	38	4/4	–
Speech delay		20	2/2	–
Squeaky voice	22		–	–
Feeding difficulties		56	4/4	–
12q14 microdeletion features				
Mental retardation	–	–	4/4	–
Osteopoikilosis	–	–	3/4	Not present at the age of 16 years

*The different sizes of the deletions in these cases have to be considered.

lesions. A convex scoliosis was noted. The girl successfully visits a grammar school (“Gymnasium”).

Sequencing of the coding region of the *HMGA2* gene in 12q14, which was deleted in patient SR29, did not reveal any pathogenic mutation neither in the remaining *HMGA2* copy of patient SR29 nor in the 19 additionally sequenced idiopathic SRS patients.

Interestingly, SRS patients share clinical features with one of these recently defined microdeletion disorders, the 12q14 microdeletion syndrome. This entity was first reported by Menten *et al*⁸ and is characterised by failure to thrive in infancy, osteopoikilosis, short stature and mental retardation. In one of these cases, the diagnosis of SRS was considered but then discarded. The three unrelated patients carried deletions ranging from 3.44 to 6 Mb (figure 2). Among other genes, in all patients, the *LEMD3* gene was deleted, which was previously shown to be the causal gene for osteopoikilosis (for review⁸), an uncommon and usually asymptomatic benign sclerosing bone dysplasia. Two further genes in the common deleted regions were *GRIP1* and *HMGA2*. The glutamate receptor interacting protein 1 (*GRIP1*) is highly expressed in foetal and adult human brain and involved in glutamatergic synaptic transmission; thus, a correlation between *GRIP1* haploinsufficiency and learning problems in the 12q14 microdeletion carriers has been proposed. For *HMGA2*, an important role in human growth as well as in lipomatosis has been postulated.^{8–9} The significance of *HMGA2* for human growth was supported by the identification of a fourth patient with a smaller 12q14 deletion¹⁰ (fig 2): in this patient, the deletion affected six genes, among others *HMGA2* and *GRIP1*, but not *LEMD3*. Indeed, this patient did not show radiological signs of osteopoikilosis but prenatal and postnatal growth retardation, failure to thrive and mild developmental delay. Interestingly, a clinical diagnosis of SRS was also considered in this patient.

The findings in our patient underline the clinical overlap between SRS and 12q14 microdeletion syndrome (table 2). However, in contrast to the other four microdeletion carriers

reported so far, our patient is not mentally handicapped; this observation is consistent with the finding that the *GRIP1* gene is not affected by the deletion in our patient. Interestingly, at an age of 16 years, our patient does not show radiographic features consistent with osteopoikilosis despite the association of *LEMD3* haploinsufficiency with this rare benign sclerosing bone dysplasia. However, the age of osteopoikilosis manifestation is currently unknown; thus, we assume that they might occur later in life in our patient. Like in the other microdeletion 12q14 patients, in our patient the *HMGA2* gene is deleted. Point mutations were not detectable in this patient; we therefore agree with Mari *et al*¹⁰ that the haploinsufficiency of this gene is sufficient to cause growth retardation. However, by screening another 20 SRS patients for point mutations in *HMGA2*, we did not obtain evidence for a significant role of this gene for the aetiology of SRS.

Up to now, all screening studies for submicroscopic chromosomal imbalances were focused on patients with mental retardation as the main clinical feature. Our data as well as recently published reports on single growth retarded patients with cryptic imbalances—that is, in 11p15^{11–12}—show that loss or gain of genomic fragments with a size of several megabases does not automatically cause intellectual incapacities. Indeed, genomic CNAs should generally be considered in patients with intrauterine and postnatal growth retardation and minor further anomalies but with normal intelligence. In SRS, molecular karyotyping should be included in the diagnostic algorithm.

Databases/links

- ▶ <http://www.ensembl.org>
- ▶ <http://www.r-project.org>
- ▶ <http://www.progenetix.net>
- ▶ <http://www.genome.ucsc.edu>
- ▶ <http://projects.tcag.ca/variation/>

Acknowledgements We thank all families who participated in this study.

Funding The project was supported by Pfizer GmbH, Germany.

Ethics approval This study was conducted with the approval of the University Hospital Aachen.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **Netchine I**, Rossignol S, Dufourg MN, Azzi S, Rousseau A, Perin L, Houang M, Seunou V, Esteve B, Thibaud N, Demay M-CR, Danton F, Petricko E, Bertrand A-M, Heirichs C, Carel J-C, Loeuille G-A, Pinto G, Jaquemont M-L, Gicquel C, Cabrol S, Le Bouc Y. 11p15 ICR1 loss of methylation is a common and specific cause of typical Russell–Silver syndrome: clinical scoring system and epigenetic-phenotypic correlations. *J Clin Endocrin Metab* 2007;**92**:3148–4154.
2. **Eggermann T**, Eggermann K, Schönherr N. Growth retardation versus overgrowth: Silver–Russell syndrome is genetically opposite to Beckwith–Wiedemann syndrome. *Trends Genet* 2008;**24**:195–204.
3. **Kotzot D**. Maternal uniparental disomy 7 and Silver–Russell syndrome—clinical update and comparison with other subgroups. *Eur J Med Genet* 2008;**51**:444–51.
4. **Shaffer LG**, Bejjani BA, Torchia B, Kirkpatrick S, Coppinger J, Ballif BC. The identification of microdeletion syndromes and other chromosome abnormalities: cytogenetic methods of the past, new technologies for the future. *Am J Med Genet* 2007;**145C**:335–45.
5. **Ashar HR**, Schoenberg F, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. *Cell* 1995;**82**:57–65.
6. **Baudis M**, Cleary ML. Progenetix.net: an online repository for molecular cytogenetic aberration data. *Bioinformatics* 2001;**17**:1228–9.
7. **Bengtsson H**, Irizarry R, Carvalho B, Speed TP. Estimation and assessment of raw copy numbers at the single locus level. *Bioinformatics* 2008;**24**:759–67.
8. **Menten B**, Buysse K, Zahir F, Hellemans J, Hamilton SJ, Costa T, Fragerstron C, Anadiotis G, Kingsbury D, McGillivray BC, Marra MA, Friedman JM, Speleman F, Mortier G. Osteopoikilosis, short stature and mental retardation as key features of a new microdeletion syndrome on 12q14. *J Med Genet* 2007;**44**:264–8.
9. **Ligon AH**, Moore SDP, Parisi MA, Mealiffe ME, Harris DJ, Ferguson HL, Quade BJ, Morton CC. Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. *Am J Hum Genet* 2005;**76**:340–8.
10. **Mari F**, Hermanns P, Giovannucci-Uzielli ML, Galluzzi F, Scott D, Lee B, Renieri A, Unger S, Zabel B, Superti-Furga A. Refinement of the 12q14 microdeletion syndrome: primordial dwarfism and developmental delay with or without osteopoikilosis. *Eur J Hum Genet* 2009;**17**:1141–7.
11. **Schönherr N**, Meyer E, Schmidt A, Wollmann HA, Eggermann T. The centromeric 11p15 imprinting center is also involved in Silver–Russell syndrome. *J Med Genet* 2007;**44**:59–63.
12. **Eggermann T**, Meyer E, Obermann C, Heil I, Schüler H, Ranke MB, Eggermann K, Wollmann HA. Is maternal duplication 11p15 associated with Silver–Russell syndrome? *J Med Genet* 2005;**42**:e26.
13. **Wollmann HA**, Kirchner T, Enders H, Preece MA, Ranke MB. Growth and symptoms in Silver–Russell syndrome: review on the basis of 386 patients. *Eur J Pediatr* 1995;**154**:958–68.
14. **Price SM**, Stanhope R, Garrett C, Preece MA, Trembath RC. The spectrum of Silver–Russell syndrome: a clinical and molecular genetic study and new diagnostic criteria. *J Med Genet* 1999;**36**:837–42.



Submicroscopic chromosomal imbalances in idiopathic Silver –Russell syndrome (SRS): the SRS phenotype overlaps with the 12q14 microdeletion syndrome

S Spengler, N Schönherr, G Binder, H A Wollmann, S Fricke-Otto, R Mühlenberg, B Denecke, M Baudis and T Eggermann

J Med Genet 2010 47: 356-360 originally published online September 16, 2009

doi: 10.1136/jmg.2009.070052

Updated information and services can be found at:
<http://jmg.bmj.com/content/47/5/356>

These include:

References

This article cites 14 articles, 6 of which you can access for free at:
<http://jmg.bmj.com/content/47/5/356#BIBL>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Calcium and bone](#) (307)
[Connective tissue disease](#) (97)
[Genetic screening / counselling](#) (886)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>